Petrelintide (5mg/10mg)

What is Petrelintide?

Zealand Pharma's long-acting amylin analog engineered for once-weekly dosing — pursuing satiety and glycemic control through a non-incretin mechanism distinct from GLP-1 / GIP agonists.

Listed vial contents: 5mg / 10mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

What mechanisms are being studied?

Petrelintide is a long-acting analog of human amylin (the pancreatic beta-cell co-hormone secreted with insulin). It activates amylin and calcitonin receptors in the brainstem area postrema, producing satiety, slowed gastric emptying, and post-prandial glucagon suppression. Because amylin signaling is mechanistically distinct from GLP-1 / GIP, petrelintide is studied as a non-incretin satiety pathway and as a combination partner for incretin agonists.

What are the research questions?

• Obesity research: Phase 2 monotherapy reported ~8.6% mean weight loss at 16 weeks across dose arms.
• Combination research: Studied alongside semaglutide and other GLP-1 agonists, testing whether amylin + GLP-1 (analogous to cagrilintide + semaglutide / CagriSema) improves efficacy and tolerability.
• GI-tolerability comparator: Used in studies investigating whether non-incretin satiety pathways produce less nausea / vomiting at equivalent weight-loss magnitudes.
• Glycemic-control research: Beta-cell-derived signaling mechanism gives a complementary glucose-regulation profile to incretin agonists.

What does the published work describe?

Zealand Pharma Phase 1b (2024) — dose-dependent weight loss over 16 weeks with favorable GI tolerability. Zealand / Boehringer Ingelheim Phase 2 ZUPREME-1 (2025) — ~8.6% mean weight loss at 16 weeks. Phase 3 program planned for 2026.

What are the limits of this evidence?

The research described concerns the cited experimental materials and models, not proof that this supplied vial is a treatment. Cell or animal findings do not establish human benefits. Clinical findings, where cited, apply to the tested formulation and population; they do not validate this research product for human use.

Study references

1. Zealand Pharma Petrelintide Phase 1b disclosure, 2024
2. Zealand / Boehringer Ingelheim Phase 2 ZUPREME-1 disclosure, 2025
3. Lutz TA. Physiol Behav 2010 — amylin pharmacology

These are the catalog's existing bibliographic references. No new source verification is implied by this presentation.

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. Generated sample reports illustrate the reporting flow and are not evidence of testing, purity or accreditation.